Stock 300497 JIANGXI FUSHINE PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Jiangxi Fushine Pharmaceutical Co., Ltd.

Equities

300497

CNE1000024Z7

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 27/06/2024 BST 		5-day change 1st Jan Change
8.93 CNY +0.45% Intraday chart for Jiangxi Fushine Pharmaceutical Co., Ltd. -3.67% -4.59%
04-28 Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-28 Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Fushine Pharma's Unit Gets Nod for Tazobactam Sodium
MT
Fushine Pharmaceutical's Unit Gets Nod to Market Antidepressant
MT
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Jiangxi Fuxiang Pharma to Invest 32.5 Million Yuan in New Biotechnology Unit
MT
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Fuxiang Pharma's Profit to Rise in H1
MT
Fushine Pharma Earmarks 386 Million Yuan to Build New Chemical Factory
MT
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.
CI
Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 4, 2021, has expired with 11,355,900 shares, representing 2.09% for CNY 174.83 million.
CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.
CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.
CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300497 Stock
  4. News Jiangxi Fushine Pharmaceutical Co., Ltd.
  5. Highlights